Table 1.
Recent findings on the roles of anti-OxLDL in atherosclerosis and relevant diseases
| Studies | Antibodies | Objective | Conclusion |
|---|---|---|---|
| Beger [5] | Anti-oxLDL/β2GPI | Arterial & venous disease [H] | Pathogenic |
| Babakr [18] | Anti-oxLDL | Impaired glucose tolerance and type 2 diabetes mellitus [H] | Pathogenic |
| Nowak [33] | Anti-oxLDL & anti-oxLDL/β2GPI (IgG and IgM) | Systemic lupus erythematosus [H] | Pathogenic |
| Tsiantoulas [38] | Anti-oxLDL (IgM) | ST-segment elevation myocardial infarction (STE-MI) [H] | Protective |
| Gironi [34] | Anti-oxLDL | Multiple sclerosis (MS) [H] | Protective |
| Izar [13] | Anti-oxLDL | Metabolic syndrome (MetS) with Acute coronary syndrome (ACS) [H] | Protective |
| Hosseini [35] | Anti-oxLDL (IgM) | Atherosclerosis [M] | Protective |
| Orbom [36] | Anti-oxLDL | Atherosclerosis [M] | Protective |
| Suthers [37] | Anti-oxLDL | Pneumococcal vaccination people [H] | Protective |
| Moohehati [39] | Anti-oxLDL (IgG) | Coronary artery disease (CAD) [H] | None |
| Sevince oK [40] | Anti-oxLDL | Hemodialysis patients [H] | None |
Footnotes: [H]: Human; [M]: Mice; None: nether pathogenic nor protective.